ArticleCost effectiveness and resource allocation : C/E2016

What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.

Jonathan Karnon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.